Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.56 |
| ▸ | RORC | P51449 | 5/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4616532 | 0.93 | MMP1 (0.49) | MMP1RORCKEAP1NFE2L2MGLL | |
| SCHEMBL6813135 | 0.93 | MMP1 (0.67) | MMP1RORCKEAP1NFE2L2KMT2A | |
| SCHEMBL4614633 | 0.90 | MMP1 (0.44) | MMP1RORCKEAP1NFE2L2MGLL | |
| SCHEMBL6813465 | 0.83 | MMP1 (0.55) | MMP1RORCKMT2AMAPTNPSR1 | |
| SCHEMBL6809611 | 0.82 | MMP1 (0.54) | MMP1RORCKEAP1NFE2L2TAS2R14 | |
| SCHEMBL4615702 | 0.82 | MMP1 (0.39) | MMP1RORCKEAP1NFE2L2MGLL | |
| SCHEMBL4783958 | 0.81 | MMP1 (0.79) | MMP1KMT2A | |
| SCHEMBL4614179 | 0.80 | MMP1 (0.51) | MMP1RORCKEAP1NFE2L2KMT2A | |
| SCHEMBL4616085 | 0.77 | MMP1 (0.56) | MMP1KMT2ACA12CA2TAS2R14 | |
| SCHEMBL14302914 | 0.76 | MMP1 (0.66) | MMP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190105409-A9 | IMAGING AGENTS WITH IMPROVED PHARMACOKINETIC PROFILES | GE HEALTHCARE AS (NO) | 2019-04-11 | — | — | US | disclosed |
| US-20140286866-A1 | IMAGING AGENTS WITH IMPROVED PHARMACOKINETIC PROFILES | GE HEALTHCARE AS (NO) | 2014-09-25 | — | — | US | disclosed |
| US-20120269727-A1 | IMAGING AGENTS WITH IMPROVED PHARMACOKINETIC PROFILES | GE HEALTHCARE AS (NO) | 2012-10-25 | — | — | US | disclosed |
| US-20080095704-A1 | A polyoxyethylene glycol having a molecular weight of < 3000 Da and 2-50 ethylene glycol units, an imageable moiety anda non-peptidic vector moiety provided that the vector does not have affinity for the Angiotensin II receptor; enhanced contrast; tomography (SPECT); PET sccans; MRIs | GE HEALTHCARE AS (NO) | 2008-04-24 | — | — | US | disclosed |
| EP-1682113-B1 | INHIBITOR IMAGING AGENTS | GE HEALTHCARE LTD (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-20070104644-A1 | Inhibitor imaging agents | CUTHBERTSON ALAN | 2007-05-10 | — | — | US | disclosed |
| EP-1682113-A1 | INHIBITOR IMAGING AGENTS | GE Healthcare Limited (GB) | 2006-07-26 | — | — | EP | disclosed |
| WO-2006004429-A2 | IMAGING AGENTS COMPRISING A NON- PEPTIDIC VECTOR LINKED TO A FLUOROPHORE VIA A POLYETHYLENE GLYCOL LINKER | GE HEALTHCARE AS (NO) | 2006-01-12 | — | — | WO | disclosed |
| WO-2005049005-A1 | INHIBITOR IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| EP-0895988-B1 | Arylsulfonylamino hydroxamic acid derivatives | PFIZER PROD INC (US) | 2002-05-22 | — | — | EP | disclosed |
| US-6107337-A | ANTIARTHRITIC AGENTS; ANTICARCINOGENIC AGENTS | PFIZER INC. (US) | 2000-08-22 | — | — | US | disclosed |
| EP-0895988-A1 | Arylsulfonylamino hydroxamic acid derivatives | Pfizer Products Inc. (US) | 1999-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080095704-A1 | A polyoxyethylene glycol having a molecular weight of < 3000 Da and 2-50 ethylene glycol units, an imageable moiety anda non-peptidic vector moiety provided that the vector does not have affinity for the Angiotensin II receptor; enhanced contrast; tomography (SPECT); PET sccans; MRIs | AGTR1, AGTR2, AVPR1A | MMP1 342/4885RORC 4761/4885KEAP1 3927/4885 |
| US-20190105409-A9 | IMAGING AGENTS WITH IMPROVED PHARMACOKINETIC PROFILES | SLC10A1, SLC10A2, SLC19A1 | MMP1 1627/4885RORC 3917/4885KEAP1 1643/4885 |
| US-20140286866-A1 | IMAGING AGENTS WITH IMPROVED PHARMACOKINETIC PROFILES | SLC10A1, SLC10A2, SLC19A1 | MMP1 1627/4885RORC 3917/4885KEAP1 1643/4885 |
| US-20120269727-A1 | IMAGING AGENTS WITH IMPROVED PHARMACOKINETIC PROFILES | SLC10A1, SLC10A2, SLC19A1 | MMP1 1627/4885RORC 3917/4885KEAP1 1643/4885 |
| US-20070104644-A1 | Inhibitor imaging agents | MMP3, MMP1, MMP10 | MMP1 2/4885RORC 4877/4885KEAP1 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.